Skip to main content

Kalia Kumud's Form 4 filing

Guardant Health, Inc. (GH) · filed Mar 5, 2026

Accession no.
0001927831-26-000004
Filed
Mar 5, 2026
Trade date
Mar 4, 2026
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 8 non-derivative transactions and 6 derivative transactions. Open-market sales total $3.81M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kalia KumudCIK 0001927831Officer (Chief Information Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 4, 2026Common StockMOption exerciseAcquired+2,119$47.20+$100,016.836,643Direct
Mar 4, 2026Common StockMOption exerciseAcquired+15,000$47.20+$708,00051,643Direct
Mar 4, 2026Common StockMOption exerciseAcquired+1,000$74.00+$74,00052,643Direct
Mar 4, 2026Common StockMOption exerciseAcquired+5,000$32.86+$164,30057,643Direct
Mar 4, 2026Common StockMOption exerciseAcquired+10,000$28.37+$283,70067,643Direct
Mar 4, 2026Common StockMOption exerciseAcquired+10,000$28.61+$286,10077,643Direct
Mar 4, 2026Common StockSSaleDisposed−26,980$95.12F1−$2,566,337.650,663Direct
Mar 4, 2026Common StockSSaleDisposed−13,020$95.73F2−$1,246,404.637,643Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 4, 2026Common StockMOption exerciseDisposed−2,119$0.00$049,305Direct
Mar 4, 2026Common StockMOption exerciseDisposed−15,000$0.00$034,305Direct
Mar 4, 2026Common StockMOption exerciseDisposed−1,000$0.00$027,670Direct
Mar 4, 2026Common StockMOption exerciseDisposed−5,000$0.00$06,414Direct
Mar 4, 2026Common StockMOption exerciseDisposed−10,000$0.00$09,410Direct
Mar 4, 2026Common StockMOption exerciseDisposed−10,000$0.00$025,721Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $94.460 to $95.455. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Referenced by the price of 1 transaction in Table I.

F2

Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $95.46 to $96.14. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)